An Open Randomised Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ as Adjuvant Therapies in Post-Menopausal Women With Breast Cancer Already Being Treated With NOLVADEX for at Least Two Years
N/A
75 Years
Female
Breast Cancer
Trial Information
An Open Randomised Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ as Adjuvant Therapies in Post-Menopausal Women With Breast Cancer Already Being Treated With NOLVADEX for at Least Two Years
Inclusion Criteria:
- Post-menopausal status; age ≤75 years;
- histologically confirmed invasive breast cancer with metastases in the axillary lymph
nodes;
- oestrogen receptor status positive or unknown;
- primary treatment (surgery +/- radiotherapy, +/- chemotherapy) completed
Exclusion Criteria:
- Clinical evidence of metastatic disease (including local or remote recurrence, even
if the patient appeared to be in complete remission at the time of randomisation).
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
The primary objective of this analysis was to assess the difference in disease-free survival between post-menopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued on tamoxifen
Principal Investigator
AstraZeneca Arimidex Medical Science Director, MD
Investigator Role:
Study Director
Investigator Affiliation:
AstraZeneca
Authority:
Italy: National Monitoring Centre for Clinical Trials - Ministry of Health
Study ID:
1033IT/0002
NCT ID:
NCT00286117
Start Date:
March 1998
Completion Date:
May 2006
Related Keywords:
- Breast Cancer
- Breast Cancer
- Breast Neoplasms
Name | Location |
|---|
